| abstract |
The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: n n n n n n n n n n wherein X is (CH 2 ) n where n is 0, 1 or 2; n R 1 , R 2 , R 3 , R 4 and R 5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R 1 , R 2 , R 3 , R 4 and R 5 may together form a methylenedioxy or ethylenedioxy moiety; n n n n n n n n n n n n R 6 , R 7 , R 8 and R 9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring;n nand the pharmacologically active salts thereof. |